pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2019-29-5-625-631pulmo-1233Research ArticleЗАМЕТКИ ИЗ ПРАКТИКИPRACTICAL NOTESЭффективность меполизумаба при длительной терапии тяжелой эозинофильной бронхиальной астмы (клинические наблюдения)Efficacy of long-term treatment with mepolizumab in severe eosinophilic asthma (case reports)ЧернякБ. А.ChernyakB. A.

Черняк Борис Анатольевич – доктор медицинских наук, профессор, заведующий кафедрой  клинической аллергологии  и пульмонологии.

664079,  Иркутск,  мкр Юбилейный,  100.

тел.: (9025) 68-78-70

Boris A.  Chernyak - Doctor  of Medicine,   Professor,  Head  of Department of Clinical  Allergology and  Pulmonology,   Irkutsk  State  Medical  Academy  of Postgraduate  Training  – a branch  of Russian Federal  Academy of Continued Medical  Education, Healthcare Ministry of Russia.

mkr Yubileynyy 100, Irkutsk, 664079.

ba.chernyak@gmail.comВоржеваИ. И.VorzhevaI. I.

Воржева Ирина Ивановна – кандидат медицинских наук, доцент кафедры  клинической аллергологии  и пульмонологии.

664079,  Иркутск,  мкр Юбилейный,  100.

тел.: (9025) 68-78-70

Irina I. Vorzheva - Candidate  of Medicine,  Associate Professor,  Department of Clinical  Allergology and  Pulmonology,  Irkutsk  State  Medical  Academy  of Postgraduate  Training  – a branch  of Russian Federal  Academy of Continued Medical  Education, Healthcare Ministry of Russia.

mkr Yubileynyy 100, Irkutsk, 664079.

vorzheva.irina@gmail.comИвановА. Ф.IvanovA. F.

Иванов Александр Федорович – кандидат медицинских наук, ассистент  кафедры  клинической аллергологии  и пульмонологии.

664079,  Иркутск,  мкр Юбилейный,  100.

тел.: (9025) 68-78-70

Aleksandr F. Ivanov - Candidate  of Medicine,  Assistant Lecturer,  Department of Clinical  Allergology and Pulmonology,  Irkutsk State  Medical  Academy of Postgraduate  Training – a branch of Russian Federal Academy of Continued Medical Education, Healthcare Ministry of Russia.

mkr Yubileynyy 100, Irkutsk, 664079.

afivanov@rambler.ruИркутская государственная медицинская академия последипломного образования – филиал Федерального государственного бюджетного образовательного учреждения дополнительного профессионального образования «Российская медицинская академия непрерывного профессионального образования» Министерства здравоохранения Российской ФедерацииРоссияIrkutsk State Medical Academy of Postgraduate Training – a branch of Russian Federal Academy of Continued Medical Education, Healthcare Ministry of RussiaRussian Federation201925122019295625631Copyright © Черняк Б.А., Воржева И.И., Иванов А.Ф., 20192019Черняк Б.А., Воржева И.И., Иванов А.Ф.Chernyak B.A., Vorzheva I.I., Ivanov A.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/1233

Представлены 2 собственных  клинических наблюдения длительной  (38 и 45 мес.) терапии препаратом  меполизумаб  больных тяжелой эозинофильной бронхиальной астмой (БА). В представленных наблюдениях проиллюстрирована эффективность меполизумаба при различных фенотипах  – аллергическом и неаллергическом (аспириновая БА). При терапии  указанным препаратом  в обоих случаях в течение ≥ 3 лет отмечен значительный клинический эффект. Важными  компонентами успешного  лечения  в приведенных наблюдениях, помимо  уменьшения выраженности симптомов  тяжелой БА и снижения частоты ее обострений, явились  преодоление зависимости от глюкокортикостероидов, а также высокая степень безопасности препарата.

Two clinical cases of severe eosinophilic asthma taking long-term  therapy with mepolizumab  (38 and 45 months are described in the article. Both the cases demonstrate  the effectiveness of the drug both in allergic and non-allergic  (aspirin-induced) asthma. Significant clinical improvement  was achieved in both cases under the treatment with mepolizumab  during ≥ 3 years. Important results of the treatment were improvement  in symptoms of severe asthma, reduction in exacerbation rate, and, additionally,  overcoming corticosteroid  addiction in patients. The therapy with mepolizumab was highly safe.

тяжелая эозинофильная бронхиальная астмамеполизумабsevere eosinophilic asthmamepolizumabАвторы статьи получали исследовательский грант в связи с участием в многоцентровом рандомизированном контролируемом исследовании по меполизумабу, проводимом фармацевтической компанией ГлаксоСмитКляйн.The authors participated in a multi-center randomized controlled study of mepolizumab supported by GlaxoSmithKline company.ReferencesWenzel S.E., Schwartz L.B., Langmack E.L. et al. Evidence that severe asthma can be divided pathologically into two inf lammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med. 1999; 160 (3): 1001–1008. DOI: 10.1164/ajrccm.160.3.9812110.Wenzel S.E., Schwartz L.B., Langmack E.L. et al. Evidence that severe asthma can be divided pathologically into two inf lammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med. 1999; 160 (3): 1001–1008. DOI: 10.1164/ajrccm.160.3.9812110.Price D.B., Rigazio A., Campbell J.D. et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir. Med. 2015; 3 (11): 849–858. DOI: 10.1016/S2213-2600(15)00367-7.Price D.B., Rigazio A., Campbell J.D. et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir. Med. 2015; 3 (11): 849–858. DOI: 10.1016/S2213-2600(15)00367-7.de Groot J.C., Storm H., Amelink M. et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res. 2016; 2 (2): pii: 00100-2015.4. DOI: 10.1183/23120541.00100-2015.de Groot J.C., Storm H., Amelink M. et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res. 2016; 2 (2): pii: 00100-2015.4. DOI: 10.1183/23120541.00100-2015.Schleich F.N., Chevremont A., Paulus V. et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur. Respir. J. 2014; 44 (1): 97–108. DOI: 10.1183/09031936.00201813.Schleich F.N., Chevremont A., Paulus V. et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur. Respir. J. 2014; 44 (1): 97–108. DOI: 10.1183/09031936.00201813.Buhl R., Humbert M., Bjermer L. et al. Severe eosinophilic asthma: a roadmap to consensus. Eur. Respir. J. 2017; 49 (5): pii: 1700634. DOI: 10.1183/13993003.00634-2017.Buhl R., Humbert M., Bjermer L. et al. Severe eosinophilic asthma: a roadmap to consensus. Eur. Respir. J. 2017; 49 (5): pii: 1700634. DOI: 10.1183/13993003.00634-2017.Chung K.F. Precision medicine in asthma: linking phenotypes to targeted treatments. Curr. Opin. Pulm. Med. 2018; 24 (1): 4–10. DOI: 10.1097/MCP.0000000000000434.Chung K.F. Precision medicine in asthma: linking phenotypes to targeted treatments. Curr. Opin. Pulm. Med. 2018; 24 (1): 4–10. DOI: 10.1097/MCP.0000000000000434.Pelaia C., Vatrella A., Busceti M.T. et al. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des. Devel. Ther. 2017; 11: 3137–3144. DOI: 10.2147/DDDT.S150656.Pelaia C., Vatrella A., Busceti M.T. et al. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab. Drug Des. Devel. Ther. 2017; 11: 3137–3144. DOI: 10.2147/DDDT.S150656.Haldar P., Brightling C.E., Hargadon B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009; 360: 973–984. DOI: 10.1056/NEJMoa0808991.Haldar P., Brightling C.E., Hargadon B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009; 360: 973–984. DOI: 10.1056/NEJMoa0808991.Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 651–659. DOI: 10.1016/S0140-6736(12)60988-X.Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicenter, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 651–659. DOI: 10.1016/S0140-6736(12)60988-X.Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371: 1198–1207. DOI: 10.1056/NEJMoa1403290.Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371: 1198–1207. DOI: 10.1056/NEJMoa1403290.Bel E.H., Wenzel S.E., Thompson P.J. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 2014; 371: 1189–1197. DOI: 10.1056/NEJMoa1403291.Bel E.H., Wenzel S.E., Thompson P.J. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 2014; 371: 1189–1197. DOI: 10.1056/NEJMoa1403291.Albers F.C., Price R.G., Smith S.G., Yancey S.W. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. J. Allergy Clin. Immunol. 2017; 140 (5): 1464–1466.e4. DOI: 10.1016/j.jaci.2017.06.010.Albers F.C., Price R.G., Smith S.G., Yancey S.W. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. J. Allergy Clin. Immunol. 2017; 140 (5): 1464–1466.e4. DOI: 10.1016/j.jaci.2017.06.010.Черняк Б.А., Воржева И.И. Эффективность и безопасность меполизумаба при тяжелой эозинофильной астме: обзор литературы. Фарматека. 2019; 11: 10–20. DOI: 10.18565/pharmateca.2019.11.10-20.Chernyak B.A., Vorzheva I.I. [Efficacy and safety of mepolizumab in severe eosinophilic asthma: a review]. Farmateka. 2019; 11: 10–20. DOI: 10.18565/pharmateca.2019.11.10-20 (in Russian).Lugogo N., Domingo C., Chanez P. et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin. Ther. 2016; 38 (9): 2058–2070.е1. DOI: 10.1016/j.clinthera.2016.07.010.Lugogo N., Domingo C., Chanez P. et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin. Ther. 2016; 38 (9): 2058–2070.е1. DOI: 10.1016/j.clinthera.2016.07.010.Khatri S., Moore W., Gibson P.G. et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J. Allergy Clin. Immunol. 2019; 143 (5): 1742–1751.е7. DOI: 10.1016/j.jaci.2018.09.033.Khatri S., Moore W., Gibson P.G. et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J. Allergy Clin. Immunol. 2019; 143 (5): 1742–1751.е7. DOI: 10.1016/j.jaci.2018.09.033.Gevaert P., van Bruaene N., Cattaert T. et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J. Allergy Clin. Immunol. 2011; 128 (5): 989–995.е8. DOI: 10.1016/j.jaci.2011.07.056.Gevaert P., van Bruaene N., Cattaert T. et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J. Allergy Clin. Immunol. 2011; 128 (5): 989–995.е8. DOI: 10.1016/j.jaci.2011.07.056.Bachert C., Sousa A.R., Lund V.J. et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J. Allergy Clin. Immunol. 2017; 140 (4): 1024–1031.е14. DOI: 10.1016/j.jaci.2017.05.044.Bachert C., Sousa A.R., Lund V.J. et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J. Allergy Clin. Immunol. 2017; 140 (4): 1024–1031.е14. DOI: 10.1016/j.jaci.2017.05.044.Tuttle K.L., Buchheit K.M., Laidlaw T.M., Cahill K.N. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. Pract. 2018; 6 (3): 1045–1047. DOI: 10.1016/j.jaip.2018.01.038.Tuttle K.L., Buchheit K.M., Laidlaw T.M., Cahill K.N. A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J. Allergy Clin. Immunol. Pract. 2018; 6 (3): 1045–1047. DOI: 10.1016/j.jaip.2018.01.038.Cavaliere C., Incorvaia C., Frati F. et al. Recovery of smell sense loss by mepolizumab in a patient allergic to Dermatophagoides and affected by chronic rhinosinusitis with nasal polyps. Clin. Mol. Allergy. 2019; 17: 3. DOI: 10.1186/s12948-019-0106-2.Cavaliere C., Incorvaia C., Frati F. et al. Recovery of smell sense loss by mepolizumab in a patient allergic to Dermatophagoides and affected by chronic rhinosinusitis with nasal polyps. Clin. Mol. Allergy. 2019; 17: 3. DOI: 10.1186/s12948-019-0106-2.Sánchez-Jareño M., Barranco P., Romero D. et al. Severe eosinophilic allergic asthma responsive to mepolizumab after failure of 2 consecutive biologics. J. Investig Allergol. Clin. Immunol. 2019; 29 (1): 79–81. DOI: 10.18176/j.iaci.0340.Sánchez-Jareño M., Barranco P., Romero D. et al. Severe eosinophilic allergic asthma responsive to mepolizumab after failure of 2 consecutive biologics. J. Investig Allergol. Clin. Immunol. 2019; 29 (1): 79–81. DOI: 10.18176/j.iaci.0340.

The authors declare that there are no conflicts of interest present.